1. Home
  2. POR vs FOLD Comparison

POR vs FOLD Comparison

Compare POR & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Portland General Electric Co

POR

Portland General Electric Co

HOLD

Current Price

$48.87

Market Cap

5.4B

Sector

Utilities

ML Signal

HOLD

Logo Amicus Therapeutics Inc.

FOLD

Amicus Therapeutics Inc.

HOLD

Current Price

$14.28

Market Cap

4.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
POR
FOLD
Founded
1889
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Electric Utilities: Central
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.4B
4.4B
IPO Year
N/A
2007

Fundamental Metrics

Financial Performance
Metric
POR
FOLD
Price
$48.87
$14.28
Analyst Decision
Hold
Buy
Analyst Count
11
9
Target Price
$46.64
$27.56
AVG Volume (30 Days)
1.1M
20.1M
Earning Date
02-13-2026
02-18-2026
Dividend Yield
4.32%
N/A
EPS Growth
N/A
N/A
EPS
2.78
N/A
Revenue
$3,511,000,000.00
$598,704,000.00
Revenue This Year
$4.94
$21.49
Revenue Next Year
$4.82
$18.42
P/E Ratio
$17.51
N/A
Revenue Growth
5.09
21.28
52 Week Low
$39.55
$5.51
52 Week High
$51.14
$14.36

Technical Indicators

Market Signals
Indicator
POR
FOLD
Relative Strength Index (RSI) 55.77 89.90
Support Level $47.37 $14.21
Resistance Level $48.83 $14.35
Average True Range (ATR) 0.69 0.08
MACD 0.07 -0.01
Stochastic Oscillator 75.92 97.72

Price Performance

Historical Comparison
POR
FOLD

About POR Portland General Electric Co

Portland General Electric is a regulated electric utility providing generation, transmission, and distribution services in a service territory that includes about half of all Oregon residents and two-thirds of the state's business activity. The company owns (wholly or through joint ventures) 3.5 gigawatts of gas, coal, wind, and hydro generation along with 300 megawatts of energy storage.

About FOLD Amicus Therapeutics Inc.

Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.

Share on Social Networks: